

Afghanistan

Support for Vaccine: Pneumococcal This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Afghanistan						
2. Vaccine grant number:	13-AFG-08c-Y, 1315-AFG-12c-X, 1619-AFG-12c-X, 17-AFG-12c-X, 17-AFG-25a-Y, 1819-AFG-12d-X, 20-AFG-12d-X						
3. Date of Decision Letter:	30-Sep-19						
4. Date of the Partnership Framework Agreement:	30-Apr-13						
5. Programme title:	New Vaccine Support (NVS), Pneumococcal , Routine						
6. Vaccine type:	Pneumococcal						
7. Requested product presentation and formulation of vaccine:	PCV13, 4 dose(s) per vial, LIQUID						
8. Programme Duration:¹	2013-2020						
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2013-2019	2020	2021	2022	2023	2024	Total ²
Programme Budget (US\$)	105,533,217	7,338,000	-	-	-	-	112,871,217
10. Vaccine introduction grant							
	Approval						
	Year	Grant Number					Amount (US\$)
	2013	13-AFG-08c-Y					1,185,000
	Disbursement						
	Disbursement date						Amount (US\$)
	10 July, 2013						1,185,000
11. Product switch grant							
	Approval						
	<i>Approval</i>						
	Year	Grant Number					Amount (US\$)
	2017	17-AFG-25a-Y					405,821
	Disbursement						
	Disbursement date						Amount (US\$)
	16 December, 2016						405,821

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

12. Indicative Annual Amounts: ³		(subject to the terms of the Partnership Framework Agreement, if applicable)			
Type of supplies to be purchased with Gavi funds	2013-2019	2020	2021		
Number of vaccine doses		2,305,600	-		
Annual Amounts (US\$)	105,533,217	7,338,000	-		
13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
14. Self-procurement:	Not applicable				
15. Co-financing obligations:	According to the co-financing policy, the Country falls within the group: Initial self-financing				
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.					
Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024
Number of vaccine doses	168,600	-	-	-	-
Number of AD syringes	-	-	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	-	-	-	-	-
Value of vaccine doses (US\$)	488,838	-	-	-	-
Total co-financing payments (US\$) (including freight)	495,000	-	-	-	-
16. Operational support for campaigns:	Not applicable				

17. Additional Reporting Requirements:

	Due dates
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 2020 15 May 2020</p>
<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Gavi Secretariat</p>

18. Financial clarifications: Country shall provide the following clarifications to Gavi*:

Not applicable

* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.

19. Other conditions:

Not applicable

Signed By
On behalf of Gavi



Thabani Maphosa
Managing Director, Country Programmes
30 September 2019